AKRO News and Press, Akero Therapeutics Inc. From 08/14/23

2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...

2023-08-11 06:29:37 ET Akero Therapeutics press release ( NASDAQ: AKRO ): Q2 GAAP EPS of -$0.60. Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended June 30, 2023 were $658.9 million. Akero believes that its current ca...

-- Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, reported during the second quarter of 2023 -- -- Phase 3 SYNCHRONY studies on track to begin...

2023-08-10 13:48:08 ET Summary 89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-line data from a Phase 2 study for its primary drug candidate targeting NASH came out in March. Th...

SOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced two presentations of secondary and...

2023-06-12 15:19:02 ET Summary Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need. The company's lead product candidate has shown promising and highly significant results in Phase 2b trials for NASH, primary and seco...

Akero Therapeutics, Inc. (NASDAQ: AKRO) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.59% on the day to $52.48. Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restor...

2023-06-05 07:31:25 ET Akero Therapeutics ( NASDAQ: AKRO ) added ~15% pre-market Monday after highlighting the potential of its investigational liver disease therapy efruxifermin (EFX) in combination with a popular weight loss drug class called GLP-1 receptor agonists (GLP-1). ...

Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX combined with GLP-1 had normalized liver fat at week 12, compared with 10% of those treated with...

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, June 5...